Verano Holdings (VRNO) Gains from Investment Securities (2021 - 2023)
Verano Holdings' (VRNO) quarterly Gains from Investment Securities came in at -$3.5 million in Q1 2023, up 27.18% year-on-year from -$2.7 million in Q1 2022, and down 365.86% on a QoQ basis from -$744000.0 in Q4 2022.
Verano Holdings (VRNO) Gains from Investment Securities (2021 - 2023) Analysis & Trends
Verano Holdings (VRNO) has 3 years of Gains from Investment Securities data on file, last reported at -$3.5 million in Q1 2023.
- On a quarterly basis, Gains from Investment Securities rose 27.18% year-over-year to -$3.5 million in Q1 2023; TTM through Dec 2023 was -$3.5 million, a 71.13% increase from a year earlier, with the FY2023 full-year figure at -$3.5 million, up 76.37% from the prior year.
- Gains from Investment Securities for Q1 2023 stood at -$3.5 million, down from -$744000.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for VRNO reached as high as $1.2 million in Q3 2021 and fell as low as -$6.0 million in Q2 2022.
- Historically, Gains from Investment Securities has averaged -$2.7 million across 3 years, with a median of -$3.5 million in 2023.
- On a YoY basis, Gains from Investment Securities climbed as much as 83.84% in 2022 and fell as far as 141.42% in 2022.
- Year by year, Gains from Investment Securities stood at -$4.6 million in 2021, then jumped by 83.84% to -$744000.0 in 2022, then slumped by 365.86% to -$3.5 million in 2023.
- Per Business Quant data, the three most recent Gains from Investment Securities figures were -$3.5 million in Q1 2023, -$744000.0 in Q4 2022, and -$502000.0 in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Verano Holdings | 1.99 Bn | 1.91 Bn | 98.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -3.47 Mn |
| Mar 31, 2023 | -3.47 Mn |
| Dec 31, 2022 | -744,000.00 |
| Dec 31, 2022 | -744,000.00 |
| Sep 30, 2022 | -502,000.00 |
| Sep 30, 2022 | -502,000.00 |
| Jun 30, 2022 | -6.00 Mn |
| Jun 30, 2022 | -6.00 Mn |
| Mar 31, 2022 | -4.76 Mn |
| Mar 31, 2022 | -4.76 Mn |
| Dec 31, 2021 | -4.60 Mn |
| Dec 31, 2021 | -4.60 Mn |
| Sep 30, 2021 | 1.21 Mn |
| Sep 30, 2021 | 1.21 Mn |